AI Article Synopsis

  • The study aimed to examine the relationship between integral body dose from radiotherapy and levels of lymphocytopaenia in cancer patients.
  • Significant lymphocyte declines were observed after treatment, with a strong correlation found between lower pre-treatment lymphocyte counts, higher integral doses, and the use of IMRT or concurrent chemotherapy.
  • The results indicate that post-treatment lymphocytopaenia is a negative prognostic factor for patients with head and neck cancer undergoing radiotherapy.

Article Abstract

Objective: Since modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) pivot on a strategy of dose redistribution, it may increase integral dose and consequently worsening of lymphocytopaenia. In this study, our objective was twofold: first to validate the correlation between integral body dose and post-treatment lymphocytopaenia in a cohort of patients treated with curative-intent radiotherapy and second to validate its prognostic impact.

Methods And Analysis: Patients treated with curative intent radiotherapy with complete blood counts were included in the study. Data on the following variables were collected: treatment site, prescribed dose, use of concurrent chemotherapy, mean body dose, mean body volume, treatment technique and disease-free survival.

Results: A total of 116 patients were included for analysis. There was a significant decline in lymphocyte counts after radiotherapy (2.2×10/L vs 0.8×10/L; p<0.001). Multivariate linear regression analysis of post-treatment lymphocytopaenia revealed a significant correlation with pretreatment lymphocyte counts, integral body dose, use of IMRT and use of concurrent radiosensitising chemotherapy. Univariate survival analysis was performed in 37 patients with squamous cell carcinoma of the head and neck. In the Cox proportional hazards model, post-treatment lymphocyte count was statistically significant as a continuous variable (Hazard Ratio=0.998, p=0.01) and as a dichotomous variable.

Conclusion: The negative correlation between integral body dose and post-treatment lymphocytopaenia was validated, and post-treatment lymphocytopaenia is an adverse prognostic factor in patients with head and neck cancer treated with curative-intent radiotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880780PMC
http://dx.doi.org/10.1136/bmjonc-2024-000522DOI Listing

Publication Analysis

Top Keywords

integral dose
8
body dose
8
patients treated
8
dose
6
radiotherapy
5
whole-body integral
4
dose post-radiotherapy
4
post-radiotherapy lymphocytopaenia
4
lymphocytopaenia solid
4
solid tumours
4

Similar Publications

Structural investigation of an RNA device that regulates PD-1 expression in mammalian cells.

Nucleic Acids Res

February 2025

Protein-Nucleic Acid Interaction Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, United States.

Synthetic RNA devices are engineered to control gene expression and offer great potential in both biotechnology and clinical applications. Here, we present multidisciplinary structural and biochemical data for a tetracycline (Tc)-responsive RNA device (D43) in both ligand-free and bound states, providing a structure-dynamical basis for signal transmission. Activation of self-cleavage is achieved via ligand-induced conformational and dynamical changes that stabilize the elongated bridging helix harboring the communication module, which drives proper coordination of the catalytic residues.

View Article and Find Full Text PDF

CT colonography (CTC) is a CT examination, performed with low dose and typically without IV contrast media, optimized to detect colorectal polyps and cancer. Despite extensive supporting data, CTC has had variable acceptance and use over the past two decades, particularly for a main indication of colorectal cancer screening. CTC is now at an inflection point after the approval in 2025 by CMS for reimbursement of CTC performed for colorectal cancer screening.

View Article and Find Full Text PDF

Pharmaceutical Automated Reporting: An opioid stewardship tool.

J Opioid Manag

March 2025

Stewardship and Clinical Appropriateness, Saskatchewan Health Authority, Regina, Sas-katchewan, Canada. ORCID: https://orcid.org/0009-0005-2332-3923.

Objective: To develop and implement a customized clinical decision support system (CDSS) in an under-resourced health region aimed at promoting appropriate and safe opioid prescribing.

Design: The Pharmaceutical Automated Reporting (PAR) tool integrates inpatient prescription data from BDM Pharmacy (version 10) and categorizes patient information using predefined logic. It operates with Python (version 3.

View Article and Find Full Text PDF

Background: The emergence of β-lactamase-producing bacteria limits the effectiveness of β-lactam (BL) antibiotics, and the combination with a β-lactamase inhibitor (BLI) aims to counteract this resistance. However, existing guidelines primarily focus on optimizing the dosing of BLs and do not adequately address the interaction between BLs and BLIs, leading to uncertain pharmacokinetic/pharmacodynamic (PK/PD) targets and potentially suboptimal dosing strategies.

Objectives: To investigate optimal PK/PD targets and dosing strategies for avibactam (BLI) combined with ceftazidime (BL) using mechanism-based PKPD models.

View Article and Find Full Text PDF

Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!